# A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status

> **NCT02831842** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 4278 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Anti-EGFR-Containing Regimen
- **DRUG:** Bevacizumab-containing regimen
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT02831842
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-09
- **Primary completion:** 2016-06-09
- **Final completion:** 2017-11-30
- **Target enrollment:** 4278 (ACTUAL)
- **Last updated:** 2018-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02831842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02831842, "A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02831842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*